Borderline ovarian serous tumor
MONDO:0020662A low grade serous epithelial neoplasm arising from the ovary. It is characterized by an atypical proliferation of serous-type epithelial cells without evidence of stromal invasion. It is often asymptomatic but rarely it may present with abdominal pain or abdominal enlargement due to rupture or torsion.
Also known as: borderline ovarian serous neoplasm, borderline ovarian serous tumor, borderline serous neoplasm of ovary, borderline serous neoplasm of the ovary, borderline serous tumor of ovary, borderline serous tumor of the ovary, borderline serous tumour of ovary, borderline serous tumour of the ovary
1443 clinical trials for this condition and its sub-types, 11 tagged with Borderline ovarian serous tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…
Phase 1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo shows promise for Hard-to-Treat ovarian cancer
Disease control OngoingThis phase II trial is testing whether the combination of ribociclib (a targeted cancer drug) and letrozole (a hormone therapy) can shrink or stabilize tumors in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. The study enrolled 51 wom…
Phase 2 • Sponsor: Gynecologic Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug cocktail targets tough ovarian cancer in japanese women
Disease control OngoingThis phase 2 study tests a combination of two drugs, avutometinib and defactinib, in 16 Japanese patients whose low-grade serous ovarian cancer has returned after platinum-based chemotherapy. The goal is to see if the combo can shrink tumors and how safe it is. The trial is activ…
Phase 2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Ovarian tumor genes may reveal who needs stronger treatment
Knowledge-focused OngoingThis study examines genetic mutations in 20 people with serous borderline ovarian tumors, a low-risk type of ovarian growth. Researchers compare tumors with and without implants (spread) to see if certain gene changes predict a higher chance of recurrence. The goal is to learn wh…
Sponsor: Universitair Ziekenhuis Brussel • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC